BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/31/2024 7:03:00 AM | Browse: 237 | Download: 724
 |
Received |
|
2023-11-01 14:19 |
|
Peer-Review Started |
|
2023-11-01 14:21 |
|
First Decision by Editorial Office Director |
|
2023-12-07 23:06 |
|
Return for Revision |
|
2023-12-07 23:06 |
|
Revised |
|
2023-12-15 19:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-11 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-11 04:53 |
|
Articles in Press |
|
2024-01-11 04:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-25 06:12 |
|
Publish the Manuscript Online |
|
2024-01-31 07:03 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Matteo Tonnini, Clara Solera Horna and Luca Ielasi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luca Ielasi, MD, Doctor, Doctor, Department of Internal Medicine, Ospedale degli Infermi di Faenza, Viale Stradone, 9, Faenza 48018, Italy. luca.ielasi.kr@gmail.com |
| Key Words |
Hepatitis B reactivation; Hepatitis B virus; Antiviral prophylaxis; Hematologic malignancies; Chimeric antigens receptor-T cell therapy; Immune checkpoint inhibitors |
| Core Tip |
In the last few years, the advent of several new therapies has characterized the therapeutic scenario of hematologic malignancies. There is now the open issue of assessing the risk of hepatitis B virus reactivation in these patients in order to decide which patients should undergo antiviral prophylaxis. |
| Publish Date |
2024-01-31 07:03 |
| Citation |
Tonnini M, Solera Horna C, Ielasi L. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why? World J Gastroenterol 2024; 30(5): 509-511 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i5/509.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i5.509 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
